Evaluating targeted therapies in older patients with <i>TP53</i> -mutated AML-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating targeted therapies in older patients with TP53 -mutated AML

Published:2024-04-22 Issue:9 Volume:65 Page:1201-1218
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sabile Jean M.G.¹²,Swords Ronan¹²,Tyner Jeffrey W.¹³

Affiliation:

1. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

2. Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA

3. Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2344057

Reference233 articles.

1. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

2. Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations — A Distinct Stem Cell Disorder

3. The Tumor Suppressor p53: From Structures to Drug Discovery

4. Regulation of p53 in response to DNA damage

5. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP